Table 2.
Baseline Characteristics (mITT Population)
| Ibrexafungerp (n = 188) | Placebo (n = 98) | |
|---|---|---|
| Age, y | ||
| Mean ± SD | 33.5 ± 10.36 | 36.0 ± 12.46 |
| Median (min, max) | 32.5 (18, 67) | 34.0 (17, 66) |
| Race, n (%) | ||
| White | 103 (54.8) | 53 (54.1) |
| Black | 73 (38.8) | 43 (43.9) |
| Asian | 4 (2.1) | 0 |
| American Indian or Alaska Native | 2 (1.1) | 0 |
| Other | 6 (3.2) | 2 (2.0) |
| Ethnicity, n (%) | ||
| Hispanic or Latino | 54 (28.7) | 18 (18.4) |
| Non-Hispanic or Latino | 134 (71.3) | 80 (81.6) |
| BMI (kg/m2)a, n (%) | ||
| ≤35 | 144 (76.6) | 76 (77.6) |
| >35 | 44 (23.4) | 22 (22.4) |
| Diabetes mellitus | ||
| Yes | 18 (9.6) | 8 (8.2) |
| No | 170 (90.4) | 90 (91.8) |
| Composite VSS score | ||
| Median (min, max) | 9.0 (5, 18) | 9.0 (4, 17) |
| Candida species | ||
| Candida albicans | 173 (92.0) | 90 (91.8) |
| Candida glabrata | 11 (5.9) | 11 (11.2) |
| Candida tropicalis | 4 (2.1) | 1 (1.0) |
| Candida dubliniensis | 2 (1.1) | 0 |
| Candida lusitaniae | 1 (0.5) | 1 (1.0) |
| Candida parapsilosis | 1 (0.5) | 0 |
| Candida krusei | 0 | 1 (1.0) |
| Saccharomyces species | 1 (0.5) | 0 |
Abbreviations: BMI, body mass index; max, maximum; min, minimum; mITT, modified intention-to-treat; SD, standard deviation; VSS, vulvovaginal signs and symptoms.
aBaseline BMI is calculated as baseline weight/baseline height2.